|
|
|
|
|
|||
|
|
|||
|
|
|||
|
|||
|
[First Episode Schizophrenia-Related Psychosis and Substance Use Disorders: Acute Response to Olanzapine and Haloperidol] |
Primer Episodio de Psicosis Asociada con Esquizofrenia y Abuso de Sustancias: Respuesta Aguda a Olanzapina y Haloperidol |
||
|
Green AI, Tohen MF, Hamer RM, y colaboradores |
|||
|
Los autores no manifiestan conflictos de interés |
|||
|
Commonwealth Research Center and the Massachusetts Mental Health Center, Harvard Medical School, Boston; Dartmouth Medical School, Lebanon; Eli Lilly and Co., Lilly Research Laboratories, Lilly Corporate Center, Indianápolis; EE.UU. |
|||
|
ReSIIC editado en las
especialidades: |
|||
|
|
|
|
|
Sociedad Iberoamericana de Información Científica (SIIC)
|